Diagnos Inc. Advances AI Healthcare Modules
Company Announcements

Diagnos Inc. Advances AI Healthcare Modules

Diagnos Inc (TSE:ADK) has released an update.

Diagnos Inc. is ramping up its efforts to secure Health Canada and FDA approvals for four new AI analysis modules designed to enhance early detection of various retinopathies, targeting commercial launch in Q3 2024. The modules will support healthcare professionals by utilizing AI for improved analysis of eye-related diseases, thus potentially increasing the company’s revenue. Additionally, Diagnos is working towards ISO 27001 Cyber Security certification to meet customer and prospect requirements.

For further insights into TSE:ADK stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskDiagnos Inc. Grants Stock Options to Leadership
TipRanks Canadian Auto-Generated NewsdeskDIAGNOS Inc. Shareholders Approve Key Proposals
TipRanks Canadian Auto-Generated NewsdeskDiagnos Insider Ownership Shifts Post-Share Placement
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App